| Nov 15 |
Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)
|
| Nov 14 |
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...
|
| Nov 13 |
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
Seres Therapeutics: Q3 Earnings Snapshot
|
| Nov 13 |
Seres Therapeutics GAAP EPS of -$0.33 misses by $0.25
|
| Nov 13 |
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 12 |
Seres Therapeutics Q3 2024 Earnings Preview
|
| Nov 6 |
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
|
| Oct 23 |
Seres cut to underweight by JP Morgan on Vowst sale
|
